Onkologische Gemeinschaftspraxis
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Person, Contact
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting
3
1033
NA
palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation
University College, London
Leukemia, Mucositis, Oral Complications
12/24
12/25
STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting
2/3
11992
Europe
Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS
Medical Research Council
Prostate Cancer
03/26
12/30
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting
2
75
US, Europe
tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis
Baylor College of Medicine
Bladder Cancer
07/10
 
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting
N/A
30
Europe
MR LINAC
Royal Marsden NHS Foundation Trust
Prostate Cancer
08/20
08/23
NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting
N/A
10
Europe
PET-MRI
Sheffield Teaching Hospitals NHS Foundation Trust
Head and Neck Cancer
10/24
10/25
NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting
N/A
1780
Europe
Cancer Trials Ireland
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
12/29
01/38

Download Options